AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00790244
Drug: doxorubicin, ifosfamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and four.~(\>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)
Trial: NCT00790244
Drug: doxorubicin, ifosfamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 2 and 3.~(\>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)
Trial: NCT01579084
Drug: AGN-199201 Formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-199201 Formulation B applied to the face as per protocol twice daily.
Trial: NCT01579084
Drug: AGN-199201 Vehicle
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-199201 vehicle (placebo) applied to the face as per protocol twice daily.
Trial: NCT06685341
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT02176863
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution
Trial: NCT02424630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All the regional blocks in this study were performed using ropivacaine, except for arthroscopy-guided SSNB using placebo (10 mL normal saline)
Trial: NCT03607071
Drug: Prednisolone and taper
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 30 mg/d and taper 5-10 mg per 2 weeks until off at week 24.
Trial: NCT01949844
Drug: Optimark®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the cardiac MR, the contrast agent, Optimark® is administered as a bolus peripheral intravenous injection at a dose of 0.2 mL/kg (0.1 mmol/kg) and at a rate of 1 to 2 mL/sec delivered by manual injection.
Trial: NCT03483649
Drug: US-Avastin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
Trial: NCT03483649
Drug: EU-Avastin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EU-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
Trial: NCT03483649
Drug: CN-Avastin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CN-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
Trial: NCT03784105
Drug: Codeine Phosphate
RxNorm normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mL of codeine phosphate 10mg/5mL
Trial: NCT03784105
Drug: Siripus simplex
RxNorm normalized name: Ruellia simplex whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar syrup
Trial: NCT01818869
Drug: AZD8848
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses inhaled IMP via a nebulizer
Trial: NCT01818869
Drug: Placebo to match AZD8848
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses inhaled matching placebo via a nebulizer
Trial: NCT01536366
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg BIA 9-1067 (single-dose)
Trial: NCT00446368
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant will take RAD001 (Everolimus) 10mg by mouth once a day.
Trial: NCT00436267
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01902004
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills will be taken in combination with the active Namenda (Memantine) pills. Participants will initially take 1 capsule per day, which will be increased to a maximum of 1 capsule twice per day.
Trial: NCT01572805
Drug: melatonin 3mg
RxNorm normalized name: MELATONIN 3MG TAB
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To receive sublingual 3 mg melatonin before spinal of anesthesia .
Trial: NCT01572805
Drug: melatonin 6mg
RxNorm normalized name: melatonin 6 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To receive sublingual 6 mg melatonin before spinal of anesthesia .
Trial: NCT01572805
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To receive sublingual placebo tablet before spinal of anesthesia .
Trial: NCT01324076
Drug: doxorubicin-eluting beads
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00532766
Drug: Jusline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01600365
Drug: Ophthalmic gel (placebo)
RxNorm normalized name: Ophthalmic Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic gel (placebo): applied in affected eye 4 times daily for 10 days
Trial: NCT00900900
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one-time dose oral dose
Trial: NCT02401490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00442182
Drug: ITF2357
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03694964
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 patients will be randomized into the group that will receive 10 mg of citrulline and 30 patients will be randomized into the placebo group for 45 days
Trial: NCT04290208
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Acetaminophen
Trial: NCT04290208
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen liquid syrup
Trial: NCT04290208
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavored, non-medicated (placebo) liquid syrup
Trial: NCT00390845
Drug: SB681323
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 milligrams (mg)/day
Trial: NCT00390845
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04290208
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV salt solution (non-medicated)
Trial: NCT02404688
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: small amount of alcohol (quarter teaspoon), with no THC. Administered over 20 minutes.
Trial: NCT02404688
Drug: Active Ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Target BrAC of 0.04% reached over 20 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 2 drinks over 1 hour. Administered over a total of 80 minutes.
Trial: NCT02404688
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: no alcohol, administered for a total of 80 minutes.
Trial: NCT01404156
Drug: (Epirubicin Cisplatin 5-Fluorouracil / Xeloda) OR 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEOADJUVANT CHEMOTHERAPY (OPTION of CHEMO REGIMEN 1 or 2)~1) FLOT - Four x 14 day cycles FLOT preoperatively and 4 cycles postoperatively (within 4-10 weeks after surgery): 5-Fluorouracil 2600 mg/m², day 1 IV every 14 days Leucovorin 200 mg/m², day 1, IV., every 14 days Oxaliplatin 85 mg/m², day 1, IV, every 14 days Docetaxel 50mg/m2, day 1, IV, every 14 days~2) ECF / ECX - Three x 21-day cycles ECF preoperatively and 3 cycles postoperatively (within 4-10 weeks after surgery): Epirubicin (50 mg/m²,mg per square meter of body-surface area) by intravenous bolus on day 1 IV Cisplatin: 60 mg/m², mg per square meter intravenously with hydration on day 1 IV 5-Fluorouracil: 200 mg/m², mg per square meter daily for 21 days by continuous IV infusion 5-FU may be substituted with Capecitabine (Xeloda) 625mg/m2, PO BID (ECX)
Trial: NCT04446299
Drug: Bowel Prep
RxNorm normalized name: Suprep Bowel Prep Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally ingested liquid bowel preparation
Trial: NCT04436016
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol will be encapsulated for adequate blinding.
Trial: NCT00096616
Drug: Combivent® CFC MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02217410
Drug: Corticosteroids (CS)
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01022125
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01895881
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01895881
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01940887
Drug: E10030
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02754687
Drug: 11βmethyl nortestosterone dodecylcarbonate
RxNorm normalized name: 17-Ethynyl-18-methyl-19-nortestosterone
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Escalating doses of 100, 200, 400, and 800 mg 11β-MNTDC
Trial: NCT00312832
Drug: switching; dose reduction
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01906307
Drug: LJPC-501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive LJPC-501 at titrated doses, with a starting range from 1 to 100 ng/kg/min, by continuous infusion on Days 1 through 5. In Group 1, drug doses will be titrated to 5, 15, and 25 ng/kg/min, after which doses will be titrated in multiples of 25 ng/kg/min. In Groups 2-5, drug doses will be titrated by 25 ng/kg/min. Dose titrations will occur every 2 hours until a MAP of 110 mmHg is reached, maximum urine output is achieved, or a dose of 250 ng/kg/min is achieved. Dosing will then continue at the maximum dose achieved through Day 5.
Trial: NCT05269173
Drug: Flos gossypii flavonoids tablet
RxNorm normalized name: Aller-Flo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The distribution ratio between the groups was 1:1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the high-dose group, low-dose group or placebo group will be determined by the randomized system.
Trial: NCT01472016
Drug: ABT-700
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-700 will be administered by intravenous infusion at escalating dose levels on day 1 in 21-day dosing cycles. Additional subjects will be enrolled in an dose expansion cohort that will further evaluate ABT-700.
Trial: NCT01472016
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion on Day 1 and 15 in 28-day dosing cycles.
Trial: NCT02051790
Drug: florbetapir F 18
RxNorm normalized name: Florbetapir F 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No study drug will be administered in this study - scans previously acquired in the course of clinical practice.
Trial: NCT01391520
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 tablets (treatment arm assigned in double-blind, randomized manner) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
Trial: NCT00236301
Drug: CLIMASTON (drug)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLIMASTON(drug)
Trial: NCT00236301
Drug: 17 Beta-estradiol (2mg/day)and (1mg/day)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 Beta-estradiol (2mg/day)and (1mg/day)
Trial: NCT00236301
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00002488
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02966249
Drug: Dexmetomidine intravenously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of dexdemetomidine at a rate of 0.25 μg/kg/h given intravenously 10 min before spinal anesthesia in total knee arthroplasty
Trial: NCT02966249
Drug: Ringer's Lactate solution intravenously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of Ringer's Lactate solution given intravenously, starting 10 minutes before spinal anesthesia up to the end of the operation
Trial: NCT02966249
Drug: Dexmetomidine intrathecally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μgr dexmetomidine given intrathecally once for anesthesia in total knee replacement
Trial: NCT02613403
Drug: MK-3682B
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two MK- 3682B 1,136 mg FDC tablets each containing 50 mg MK-5172 (GZR), 225 mg MK-3682 (UPR, formerly IDX21437), and 30 mg MK-8408 (RZR) taken once daily by mouth.
Trial: NCT02244463
Drug: MLN0128
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03420781
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injected twice daily
Trial: NCT00411242
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04481789
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets
Trial: NCT03775902
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet
Trial: NCT03382834
Drug: Antiretroviral drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive antiretroviral drugs provided by their own doctors. Antiretroviral drugs will not be provided by the study.
Trial: NCT03220295
Drug: Placebo Dose Escalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose levels of the cohorts will be increased step wise
Trial: NCT04000438
Drug: DF01
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The subject receives sc injections of tafoxiparin solution once daily for up to 7 days until labor induction or spontaneous onset of labor. Induction is done according to clinical practice; 1st balloon, 2nd PGE1
Trial: NCT05148169
Drug: SSRIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One SSRI(No-specified) is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.
Trial: NCT01860300
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00426608
Drug: GSK561679
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK561679 tablets will be available with dose strength of 50, 10 and 200 mg.
Trial: NCT04317508
Drug: Benzocaine oral gel 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control group
Trial: NCT01762202
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02235077
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receiving no MRA at home will receive spironolactone 100 mg (4x25 mg capsules) once daily for 96 hours.~Patients already receiving low-dose MRA at home will be randomized to receive spironolactone 25 mg (1x25 mg capsules) or 100 mg (4x25 mg capsules) in hospital for 96 hours. The patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding.
Trial: NCT02235077
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving no MRA at home will receive 100 mg placebo (4x25 mg capsules) once daily for 96 hours.~Patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding.
Trial: NCT01042184
Drug: Sequential therapy for 14 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D1-D7: (lansoprazole 30mg + amoxicillin 1gm) bid D8-D14: (lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg) bi
Trial: NCT01042184
Drug: Sequential therapy for 10 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid
Trial: NCT01042184
Drug: Triple therapy for 14 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid
Trial: NCT00338598
Drug: Glycine
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycine, 0.8 gr per kg given in two daily doses
Trial: NCT00338598
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01127646
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, once daily for random nonconsecutive 6 days during 4-week treatment period.
Trial: NCT01129388
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: matching tablet~Route of administration: oral
Trial: NCT00969397
Drug: Topical Antiangiogenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Antiangiogenic
Trial: NCT03799692
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Nanoparticle Albumin-Bound Paclitaxel Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1, 8, 15.~Drug: Carboplatin AUC=2 iv, d1, 8, 15.
Trial: NCT02313909
Drug: Acetylsalicylic acid (Aspirin, BAY1019036)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg, once daily, orally, tablet
Trial: NCT00169559
Drug: GW590735
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1µg to 20µg daily doses of GW590735
Trial: NCT02054767
Drug: Intervention: inferior alveolar nerve block injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: -22 patients received inferior alveolar nerve block injections of 3.6 mL (equivalent to 2 cartridges)
Trial: NCT03492762
Drug: Cu-DOTA-ECL1i
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiolabeled probe called Cu-DOTA-ECL1i that recognizes CCR2 and propose to image CCR2 in the lung to ultimately guide diagnosis and therapy.
Trial: NCT02176577
Drug: Product 0405
RxNorm normalized name: Pyelocalyceal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Product 0405 will be administered topically, twice daily for 28 days.
Trial: NCT04057261
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo once daily, subcutaneous injection via pre-filled pen.
Trial: NCT03794076
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline nasal spray will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray)
Trial: NCT01217099
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: control patients were iv azithromycin for 5 days.
Trial: NCT00738400
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets daily for 4 weeks, placebo tablets daily for consecutive 4 weeks
Trial: NCT02698657
Drug: ASP5094
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV)
Trial: NCT01046058
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg (two 75-mg capsules) orally (by mouth) once daily for 7 days
Trial: NCT01062113
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial dose: Celecoxib 200mg tablet x 2 will be administrated during a period from 1 to 2 hours post lateral mandibular impacted third molar tooth extraction in subjects with moderate pain or severe painrated as 45.0 mm or more on the VAS
Trial: NCT01062113
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Additional dose: Celecoxib 200mg tablet x 1 will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain
Trial: NCT01062113
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional dose: Placebo (tablet) will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain
Trial: NCT00661609
Drug: AZD4877
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV)25mg/weekly
Trial: NCT02826200
Drug: Acenocoumarol
RxNorm normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care plus oral anticoagulant therapy (acenocoumarol)
Trial: NCT01430403
Drug: Inhaled Corticosteroid Boost Therapy (ICS)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered fluticasone (Flovent ® Diskus®) inhalers sufficient to deliver the required 200 mcg or 500 mcg daily boost of fluticasone. All participants will receive standardized specialist asthma care.
Trial: NCT00247650
Drug: Zoledronic Acid; Letrozole
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00509834
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00325364
Drug: Human Insulin Inhalation Powder
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient specific dose, inhaled, before meals, 24 months